Suppr超能文献

急性口服负荷剂量曲美他嗪对经皮冠状动脉介入术后心肌损伤的保护作用。

Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention.

作者信息

Bonello Laurent, Sbragia Pascal, Amabile Nicolas, Com Olivier, Pierre Sandrine V, Levy Samuel, Paganelli Franck

机构信息

Division of Cardiology, Hospital Nord, University of Marseille, School of Medicine, Marseille, France.

出版信息

Heart. 2007 Jun;93(6):703-7. doi: 10.1136/hrt.2006.107524. Epub 2007 May 8.

Abstract

OBJECTIVE

To evaluate the effect of pre-procedural acute oral administration of trimetazidine (TMZ) on percutaneous coronary intervention (PCI)-induced myocardial injury.

DESIGN

Single-centre, prospective, randomised evaluation study.

SETTING

Patients with stable angina pectoris and single-vessel disease undergoing PCI.

PATIENTS

582 patients were prospectively randomised. Patients who underwent more than one inflation during PCI were excluded, resulting in 266 patients randomly assigned to 2 groups.

INTERVENTIONS

Patients were randomly assigned to receive or not an acute loading dose of 60 mg of TMZ prior to intervention.

MAIN OUTCOME

The frequency and the increase in the level of cardiac troponin Ic (cTnI) after successful PCI. cTnI levels were measured before and 6, 12, 18 and 24 h after PCI.

RESULTS

136 patients were assigned to the TMZ group and 130 to the control group. Although no statistically significant difference was observed in the frequency of cTnI increase between the two groups, post-procedural cTnI levels were significantly reduced in the TMZ group at all time points (6 h: mean (SD) 4.2 (0.8) vs 1.7 (0.2), p<0.001; 12 h: 5.5 (1.5) vs 2.3 (0.4), p<0.001; 18 h: 9 (2.3) vs 3 (0.5), p<0.001; and 24 h: 3.2 (1.2) vs 1 (0.5), p<0.001). Moreover, the total amount of cTnI released after PCI, as assessed by the area under the curve of serial measurement, was significantly reduced in the TMZ group (p<0.05).

CONCLUSION

Pre-procedural acute oral TMZ administration significantly reduces PCI-induced myocardial infarction.

摘要

目的

评估术前急性口服曲美他嗪(TMZ)对经皮冠状动脉介入治疗(PCI)所致心肌损伤的影响。

设计

单中心、前瞻性、随机评估研究。

背景

行PCI的稳定型心绞痛单支血管病变患者。

患者

582例患者被前瞻性随机分组。排除PCI期间进行多次球囊扩张的患者,最终266例患者随机分为2组。

干预措施

患者被随机分配在干预前接受或不接受60mg TMZ的急性负荷剂量。

主要结局

成功PCI后心肌肌钙蛋白Ic(cTnI)水平升高的频率及升高幅度。在PCI术前及术后6、12、18和24小时测量cTnI水平。

结果

136例患者被分配至TMZ组,130例患者被分配至对照组。虽然两组间cTnI升高频率无统计学显著差异,但TMZ组术后各时间点的cTnI水平均显著降低(6小时:均值(标准差)4.2(0.8)对1.7(0.2),p<0.001;12小时:5.5(1.5)对2.3(0.4),p<0.001;18小时:9(2.3)对3(0.5),p<0.001;24小时:3.2(1.2)对1(0.5),p<0.001)。此外,通过连续测量曲线下面积评估,TMZ组PCI后释放的cTnI总量显著降低(p<0.05)。

结论

术前急性口服TMZ可显著降低PCI所致心肌梗死。

相似文献

2
Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S365-S371. doi: 10.1016/j.ihj.2018.10.415. Epub 2018 Nov 14.
5
Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
Heart. 2007 Jun;93(6):698-702. doi: 10.1136/hrt.2006.097477. Epub 2006 Oct 25.
8
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Am J Emerg Med. 2017 Nov;35(11):1657-1661. doi: 10.1016/j.ajem.2017.05.024. Epub 2017 May 23.

引用本文的文献

1
Cardioprotective strategies in myocardial ischemia-reperfusion injury: Implications for improving clinical translation.
J Mol Cell Cardiol Plus. 2024 Dec 16;11:100278. doi: 10.1016/j.jmccpl.2024.100278. eCollection 2025 Mar.
2
Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review.
Am J Cardiovasc Drugs. 2025 Apr 3. doi: 10.1007/s40256-025-00724-1.
4
Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S365-S371. doi: 10.1016/j.ihj.2018.10.415. Epub 2018 Nov 14.
5
Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?
Open Cardiovasc Med J. 2018 Mar 30;12:29-40. doi: 10.2174/1874192401812010029. eCollection 2018.
9
Effect of Trimetazidine in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
PLoS One. 2015 Sep 14;10(9):e0137775. doi: 10.1371/journal.pone.0137775. eCollection 2015.
10
Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.
Am J Ther. 2016 May-Jun;23(3):e871-9. doi: 10.1097/MJT.0000000000000180.

本文引用的文献

1
Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury.
J Mol Cell Cardiol. 2005 Dec;39(6):893-9. doi: 10.1016/j.yjmcc.2005.09.012. Epub 2005 Oct 21.
4
Role of the mitochondrial permeability transition in myocardial disease.
Circ Res. 2003 Aug 22;93(4):292-301. doi: 10.1161/01.RES.0000087542.26971.D4.
6
Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
Fundam Clin Pharmacol. 2003 Apr;17(2):133-45. doi: 10.1046/j.1472-8206.2003.00154.x.
7
Prognostic implication of cardiac troponin T increase following stent implantation.
Heart. 2002 Jun;87(6):549-53. doi: 10.1136/heart.87.6.549.
10
Acute and subacute stent occlusion; risk-reduction by ionic contrast media.
Eur Heart J. 2001 Mar;22(5):385-91. doi: 10.1053/euhj.2000.2319.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验